Janssen Pharmaceutical Companies of Johnson & Johnson: New Data Shows First, Only Investigational Targeted Oral Peptide
March 09, 2024
March 09, 2024
SAN DIEGO, California, March 9 (TNSres) -- The Janssen Pharmaceutical Companies of Johnson and Johnson issued the following news release:
* * *
Maintained Skin Clearance in Moderate-to-Severe Plaque Psoriasis Through One Year
* * *
Johnson & Johnson today announced the first data from FRONTIER 2, the long-term extension of the Phase 2b FRONTIER 1 clinical trial evaluating JNJ-2113, the first and only investigational targeted oral peptide de . . .
* * *
Maintained Skin Clearance in Moderate-to-Severe Plaque Psoriasis Through One Year
* * *
Johnson & Johnson today announced the first data from FRONTIER 2, the long-term extension of the Phase 2b FRONTIER 1 clinical trial evaluating JNJ-2113, the first and only investigational targeted oral peptide de . . .